Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Lilly

Status and phase: Completed; Phase 3

Conditions: Breast Neoplasms

Treatments: Drug: LY353381; Drug: tamoxifen

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034125

H4Z-MC-JWXD

3883

Details and patient eligibility

About

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Locally advanced or metastatic breast cancer
2. Bi-dimensionally measurable disease

Exclusion Criteria

1. Prior hormonal therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind